Literature DB >> 1693842

Stratum corneum antibodies detected by hemagglutination are not directed against keratin intermediate filaments.

S Qutaishat1, V Kumar, E H Beutner, S Jabłońska.   

Abstract

Autoantibodies to stratum corneum (SC) occur in virtually all normal adult human sera. These antibodies may be directed against various antigens of the SC. They have been detected by indirect immunofluorescence, passive hemagglutination (HA), immune adherence, and most recently by enzyme immunoassay and immunoblot methods. The purpose of our study was to examine whether antibodies to SC antigens as detected by passive HA are similar to the keratin intermediate filament (KIF) reactive antibodies. SC antigen preparation was prepared from psoriatic scales by the trypsin-phenol-water (TPW) extraction method. KIFs were prepared by 8 M urea extraction of normal callus or psoriatic scales. The anti-SC antibody titers of normal human sera were determined by passive HA before and after absorption with TPW-SC antigen preparation and upon absorption with KIFs. Similarly, titers of anti-KIF antibodies were determined on absorbed and unabsorbed sera by immunoblot assay. The results of this study indicate that the absorption of the sera with KIFs did not affect the titer of antibodies to TPW-extractable SC antigens whereas the titer of KIF antibodies dropped. KIF-reactive antibodies, on the other hand, were not affected by absorption with TPW-SC antigen, whereas the latter absorbed out the corresponding reactive antibodies. These results indicate that antibodies directed against SC antigen are different from the KIF-reactive antibodies.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1693842     DOI: 10.1007/bf00493464

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  18 in total

1.  Hypothesis. Auto-antibodies and immunological theories: an analytical review.

Authors:  P Grabar
Journal:  Clin Immunol Immunopathol       Date:  1975-11

Review 2.  Monoclonal antibody studies of mammalian epithelial keratins: a review.

Authors:  T T Sun; S C Tseng; A J Huang; D Cooper; A Schermer; M H Lynch; R Weiss; R Eichner
Journal:  Ann N Y Acad Sci       Date:  1985       Impact factor: 5.691

3.  Natural IgM and IgG autoantibodies to epidermal keratins in normal human sera. I: ELISA-titration, immunofluorescence study.

Authors:  G Serre; C Vincent; R Viraben; J P Soleilhavoup
Journal:  J Invest Dermatol       Date:  1987-01       Impact factor: 8.551

4.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

Review 5.  Immunopathology of psoriasis.

Authors:  S Jablonska; E H Beutner; W L Binder; M Jarzabek-Chorzelska; G Rzesa; O Chowaniec
Journal:  Arch Dermatol Res       Date:  1979-02-23       Impact factor: 3.017

6.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

7.  Isolation and characterization of intermediate filaments.

Authors:  P Steinert; R Zackroff; M Aynardi-Whitman; R D Goldman
Journal:  Methods Cell Biol       Date:  1982       Impact factor: 1.441

8.  Improvement of the glucose oxidase immunoenzyme technic. Use of a tetrazolium whose formazan is stable without heavey metal chelation.

Authors:  S C Suffin; K B Muck; J C Young; K Lewin; D D Porter
Journal:  Am J Clin Pathol       Date:  1979-05       Impact factor: 2.493

9.  Human upper epidermal cytoplasmic antibodies are directed against keratin intermediate filament proteins.

Authors:  H Hintner; P M Steinert; T J Lawley
Journal:  J Clin Invest       Date:  1983-10       Impact factor: 14.808

10.  Immunopathology of psoriasis: a comparison with other parakeratotic lesions.

Authors:  V C Weiss; H van den Broek; S Barrett; D P West
Journal:  J Invest Dermatol       Date:  1982-03       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.